Vunakizumab Shows Sustained Efficacy in Radiographic Axial Spondyloarthritis: JAMA
核心洞察
Vunakizumab 120 mg achieved a 65.6% ASAS20 response rate at week 16 compared with 42.5% for placebo, a 23.2 percentage-point improvement in patients with active r-axSpA.
The ASAS40 response rate reached 46.3% with vunakizumab versus 24.0% with placebo at week 16, and clinical benefits were maintained through 32 weeks.
Adverse events were comparable between groups (83.7% vs. 81.5%), with no unexpected safety concerns identified during the placebo-controlled period.
A novel monoclonal antibody targeting interleukin-17A has demonstrated significant and sustained clinical benefits for patients with active radiographic axial spondyloarthritis (搜索) (r-axSpA), according to findings published in JAMA Network Open. In a randomized, double-blind, placebo-controlled phase 2–3 trial, vunakizumab 120 mg administered every four weeks significantly improved disease signs and symptoms compared with placebo at 16 weeks, with responses maintained through 32 weeks.
The study, led by Jian Zhu and colleagues, enrolled 548 adults with active r-axSpA across 38 hospitals in China between June 2021 and March 2023. Following interim analyses, the 120-mg dose was selected for further evaluation. Patients received either vunakizumab 120 mg or placebo through week 16, after which all participants were treated with vunakizumab every four weeks until week 32.
Efficacy Outcomes at Week 16
The primary endpoint — the proportion of patients achieving an ASAS20 response at week 16 — was met decisively. The ASAS20 response rate reached 65.6% in the vunakizumab group compared with 42.5% in the placebo group, representing an increase of 23.2 percentage points.
On the more stringent ASAS40 measure, vunakizumab also demonstrated superiority. The ASAS40 response rate at week 16 was 46.3% with vunakizumab compared with 24.0% with placebo, an improvement of 22.3 percentage points. Secondary endpoints, including measures of disease activity, physical function, spinal mobility, and quality of life, further supported the drug's clinical benefit.
Sustained Response Through 32 Weeks
Clinical responses achieved with vunakizumab were maintained through week 32, the full duration of the study's follow-up period. This durability suggests that the IL-17A (搜索) inhibition provided by vunakizumab offers lasting symptom control in this chronic inflammatory condition, which is characterized by persistent pain, stiffness, and impaired mobility.
Safety Profile
During the placebo-controlled period, adverse events occurred in 83.7% of patients receiving vunakizumab and 81.5% of those receiving placebo. The incidence of adverse events was comparable between the two groups, and no unexpected safety concerns were identified. The researchers characterized the safety profile as manageable and well-tolerated.
Study Limitations
The investigators acknowledged several important limitations. The 32-week follow-up period, while sufficient to demonstrate early and sustained clinical response, may not capture longer-term outcomes. The trial did not include an active biologic comparator, limiting direct comparisons with existing therapies. Additionally, the study enrolled only Chinese patients, which may affect the generalizability of the findings to broader populations. Notably, radiographic outcomes were not assessed, leaving the drug's effect on long-term structural disease progression unclear.
Clinical Implications
Vunakizumab is a novel monoclonal antibody targeting interleukin-17A, a key driver of inflammation in spondyloarthritis. The findings support vunakizumab as a promising new treatment option for active radiographic axial spondyloarthritis (搜索) and potentially other IL-17–mediated inflammatory diseases. The results address an ongoing need for new therapeutic options in r-axSpA, a condition that can significantly impair quality of life through chronic pain and reduced mobility.